Yonina R. Murciano-Goroff, MD, MSc, DPhil - MSK Early Drug Development Specialist

I am a pediatric oncologist who treats children and young adults with leukemias and refractory solid tumors. In particular, I am interested in developing treatments that maximize the success of currently available therapies and devising new therapies that are precise, curative, and safe.

Timothy Donahue, MD is a renowned MSK Urologic Surgeon situated in New York, NY. Dr. Donahue specializes in treating bladder cancer, prostate cancer, kidney cancer, and penile cancer using both open and minimally invasive surgical techniques. With over 15 years of experience, Dr. Donahue cares for approximately 1,500 patients annually. As part of a top-ranked team in Urology Cancer Care by U.S. News & World Report, he focuses on guiding patients through the complexities of cancer diagnosis and treatment. Driven by a commitment to patient-centered care, Dr. Donahue prioritizes understanding each patient's goals and preferences to ensure the best possible outcomes while maintaining their quality of life. Actively engaged in bladder cancer research, he leads clinical trials to enhance surgical outcomes for radical cystectomy patients and explores innovative approaches for non-muscle invasive bladder cancer treatment. Patients benefit from cutting-edge therapies before they become widely available. Generated from the website content

Paul Chapman, MD is currently the Chief Medical Research Officer for the Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Chapman received his M.D. degree from Weill Cornell Medical College in 1981 and trained in internal medicine as an intern and resident at the University of Chicago Hospitals and Clinics from 1981-1984. After that, he returned to New York as a medical oncology Fellow at Memorial Sloan Kettering Cancer where he focused on immunotherapy of melanoma in the laboratory of Dr. Alan Houghton. He joined the faculty of Memorial Sloan Kettering Cancer Center (MSKCC) in 1988 and worked there through 2023 as a tenured Attending Physician. During this time at MSKCC, Dr. Chapman led many clinical and laboratory studies designed to develop new and improved treatments for melanoma. This included the first BRAF targeted therapy trial and several immunotherapy trials. His research continues to focus on developing new treatments for melanoma.